The unexpected and impressive activity reported for palbociclib in breast cancer patients when used in combination with anti-estrogen therapy [45] then rapidly stimulated the design of other CDK4/6 inhibitors that rapidly entered in clinical development. This evidence concerns the gene CDK4 and breast cancer.